What one share of Roivant Sciences holds
Roivant is a biopharmaceutical company that aims to improve the lives of patients by accelerating the development and commercialization of medicines that matter.
Roivant Sciences’s numbers from its SEC filings, divided by its shares. Results cover the last 12 months to 2026-06-30; the balance sheet is as of 2026-06-30.
| Sales | $0.01 |
|---|---|
| Profit | −$0.38 |
| Capex (buildings and equipment) | $0.01 |
| Free cash flow | −$1.17 |
| Cash and investments | $5.32 |
| Book value | $5.86 |
Per share by fiscal year
| Year | Sales | Profit | Capex | Free cash | Dividends | Book value |
|---|---|---|---|---|---|---|
| 2021 | $0.04 | −$1.28 | $0.01 | −$0.89 | — | $2.76 |
| 2022 | $0.08 | −$1.26 | $0.03 | −$1.04 | — | $2.38 |
| 2023 | $0.04 | −$1.42 | $0.02 | −$1.20 | — | $1.52 |
| 2024 | $0.04 | $5.23 | $0.00 | −$0.92 | — | $7.40 |
| 2025 | $0.04 | −$0.24 | $0.01 | −$1.16 | — | $6.74 |
| 2026 | $0.01 | −$0.54 | $0.01 | −$1.09 | — | $6.28 |
Common questions about Roivant Sciences
How much does one share of Roivant Sciences earn?
Over the last 12 months, Roivant Sciences lost $0.38 for each share on $0.01 of sales.
Does Roivant Sciences pay a dividend?
Roivant Sciences didn’t pay a dividend over the last 12 months, according to its SEC filings.
What is Roivant Sciences’s book value per share?
Roivant Sciences’s book value is $5.86 per share: what would be left for each share if it sold everything at the values on its books and paid every debt, as of June 30, 2026.
How much cash and debt does each share of Roivant Sciences have?
Each share of Roivant Sciences has $5.32 of cash and investments, as of June 30, 2026.
What is Roivant Sciences’s free cash flow per share?
−$1.17 per share over the last 12 months. Free cash flow is the cash left over after spending on buildings and equipment.
Has Roivant Sciences bought back shares?
Roivant Sciences’s share count rose about 10% from 2021 to 2026. That dilution means each share owns a smaller slice of the company.
From its SEC filings. For education only, not investment advice. New to these words? See the StockSlicer glossary.